About this Research Topic
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease with predominantly arthritic lesions, and its pathology is characterized by persistent synovitis, vascular opacity formation and bone erosion. It has been reported that the prevalence of RA in China has reached 0.42 % and is one of the main causes of labor loss and disability in our population, as RA can occur in all age groups and is recurrent. Although the development of novel therapies such as biologics and small molecule targeted specific cytokine drugs has shed some light on slowing down its progression, unfortunately, there is no cure so far. Therefore, it is of great significance to explore the key potential targets of RA.
The goal of this Research Topic is to share with readers the new progress and discoveries in the pathogenesis of RA, the discovery of potential therapeutic targets for RA, and the development of therapeutic drugs. It also focuses on exploring the pathogenesis, clinical treatment, and research on the new drugs of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). Therefore, the topics of this Research Topic include: research on the pathogenesis of RA and RA-ILD, such as pathophysiology, epigenetics and signal pathways, which is beneficial for improving prognosis and improving drug response; research and development of natural drugs, chemical drugs and bioengineering drugs based on novel targets of RA and RA-ILD.
In this Research Topic, we welcome researchers to submit Perspective, Original Research, Review, Commentary, Opinion, Clinical Trial and Case Report, including but not limited to the following topics:
• Research on the pathophysiological mechanisms in RA;
•Research on the new therapeutic drugs for the treatment of RA;
• Discovery of new inhibitors for treating RA;
• Discovery of novel signaling pathways in RA;
• Elucidation of mechanisms for therapeutic drugs in Rheumatoid arthritis related interstitial lung disease (RA-ILD).
The goal of this Research Topic is to share with readers the new progress and discoveries in the pathogenesis of RA, the discovery of potential therapeutic targets for RA, and the development of therapeutic drugs. It also focuses on exploring the pathogenesis, clinical treatment, and research on the new drugs of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). Therefore, the topics of this Research Topic include: research on the pathogenesis of RA and RA-ILD, such as pathophysiology, epigenetics and signal pathways, which is beneficial for improving prognosis and improving drug response; research and development of natural drugs, chemical drugs and bioengineering drugs based on novel targets of RA and RA-ILD.
In this Research Topic, we welcome researchers to submit Perspective, Original Research, Review, Commentary, Opinion, Clinical Trial and Case Report, including but not limited to the following topics:
• Research on the pathophysiological mechanisms in RA;
•Research on the new therapeutic drugs for the treatment of RA;
• Discovery of new inhibitors for treating RA;
• Discovery of novel signaling pathways in RA;
• Elucidation of mechanisms for therapeutic drugs in Rheumatoid arthritis related interstitial lung disease (RA-ILD).
Keywords: Inflammation, rheumatoid arthritis, signal pathways, molecular targets, drug
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
